Vendor Intelligence Report: Peptide Pole Hongkong

Published 2 Jul 2026. 22-page investigative report on who is behind Peptide Pole Hongkong: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Peptide Pole Hongkong is a narrow, Retatrutide-first case, not a catalog-wide endorsement. Across 6 Finnrick lab tests, the vendor records 5 passes and 1 fail, an overall pass rate of 83%. All Finnrick evidence in this dossier is Retatrutide: enough to keep PPHK in the comparison set for that peptide, but not enough to validate advertised Tirzepatide, Semaglutide, HCG, or other catalog items.

The identity file is less settled than the product score. PPHK presents as a Hong Kong Co., Ltd using a Quarry Bay address, but researchers did not find a matching Hong Kong Companies Registry/OpenCorporates record, company number, named owner, or director disclosure in the captured trail; the official registry search still needs a cleaner re-check because of e-Services loading issues.

The operating footprint also looks recent and chat-driven: a 51microshop storefront, hidden WHOIS, Los Angeles Alibaba US hosting, late-2025/early-2026 archive and forum activity, and sales relationships centered on Ella Song, Kelly Wu, Gmail, Telegram, WhatsApp, Discord, and GLP1Forum threads. Janoshik claims were not publicly corroborated under the PPHK name, and a captured Reddit warning alleges fake satisfied-customer accounts and negative-review suppression.

Buyer posture is therefore split. PPHK’s Retatrutide record is mixed-positive, especially when current-lot verification and protected checkout are used; the full report shows how that record changes under stricter scoring. The risk rises sharply for untested products, unverifiable COA screenshots, forwarded chat invites, impersonator channels, or Western Union payment.

Inside the full report:

  • Appendix A lab data, methodology-divergence chart, and trajectory view for the one Finnrick-tested product
  • Hong Kong Companies Registry/OpenCorporates search trail, entity-claim matrix, and Quarry Bay address analysis
  • Domain and infrastructure profile for peptidehk.com, including WHOIS status, IP/host, Wayback timing, and ScamAdviser capture
  • GLP1Forum and Reddit reputation file covering vendor-managed review streams, astroturfing allegations, and impersonator warnings
  • Sales-channel/personnel map for Ella Song, Kelly Wu, and historical UK/US contacts
  • Payment-method recourse analysis for card, PayPal, card-via-PayPal, and Western Union paths

Risk assessment

  • Corporate-identity and registration risk — high: PPHK claims a Hong Kong Co. Ltd/address, but field checks found no HK Companies Registry/OpenCorporates record and no registration number or owner was surfaced.
  • Forum-review manipulation risk — high: A May 29, 2026 Reddit warning alleges fake customer accounts and review censorship, while PPHK’s main review streams are vendor/sponsor-managed GLP1Forum threads.
  • Copycat and brand-confusion risk — high: PPHK has warned about impersonators, including Telegram activity, but the captured site lacks robust official-channel, authorized-reseller, COA-verification, or anti-counterfeit controls.
  • Unverified testing claims and untested catalog risk — medium: Public Janoshik search for “PPHK” returned 0 results, and Finnrick has no record for advertised non-Retatrutide products such as Tirzepatide, Semaglutide, HCG, GHK-Cu, NAD+, MOTS-C, Tesamorelin, CJC-1295, and Ipamorelin.
  • Retatrutide quality-consistency risk — medium: Retatrutide is PPHK’s only Finnrick-tested product: 6 tests, 5 pass / 1 fail, current rating 80.46%; usable signal, but not a clean lot-consistency record.
  • Operational-history and infrastructure-transparency risk — medium: The public web footprint is recent, with Facebook in Nov. 2025 and first Wayback on Feb. 25, 2026; WHOIS is hidden, and peptidehk.com is hosted on Alibaba US in Los Angeles despite Hong Kong positioning.